Clinuvel Pharmaceuticals Limited American Depositary Shares (CUVL) Stock Price

CUVLStock

$7.60−15.40%52W

Market Cap$383.25M

P/E14.53x

PEG Ratio0.84

Div yield0.29%

Beta0.31

CUVL Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-20.41%

Price vs S&P 500 (4W)7.48%

PEG Ratio0.84

VGM Score48.28

P/E Ratio (Annual)14.53x

Indicated Dividend Yield (Annual)0.29%

P/CF (Annual)12.79x

Book Value / Share (Quarterly)$3.55

P/TBV (Annual)5.03x

Indicated Dividend (Annual)$0.04

Revenue Growth (3Y)12.82%

Cash Flow / Share (Quarterly)$0.57

Payout Ratio (TTM)7.70%

Price vs S&P 500 (YTD)-25.53%

Gross Margin (TTM)94.53%

Net Profit Margin (TTM)33.79%

EPS (TTM)$0.46

10-Day Avg Trading Volume0.12M

EPS Excl Extra (TTM)$0.46

Revenue Growth (5Y)23.46%

EPS (Annual)$0.51

Dividend / Share (Annual)$0.04

ROI (Annual)14.99%

Gross Margin (Annual)95.29%

Net Profit Margin (5Y Avg)39.07%

Cash / Share (Quarterly)$3.32

P/E Basic Excl Extra (TTM)16.15x

Revenue Growth QoQ (YoY)3.60%

EPS Growth (5Y)19.20%

P/E Normalized (Annual)14.53x

ROA (Last FY)13.31%

Revenue Growth TTM (YoY)0.95%

EBITD / Share (TTM)$0.62

ROE (5Y Avg)18.57%

Operating Margin (TTM)44.63%

Cash Flow / Share (Annual)$0.58

P/B Ratio2.11x

P/B Ratio (Quarterly)2.52x

EV / Revenue (TTM)5.08x

Net Interest Coverage (TTM)21.55x

ROA (TTM)12.02%

EPS Growth QoQ (YoY)-26.32%

EV / EBITDA (TTM)11.12x

EPS Incl Extra (Annual)$0.51

Current Ratio (Annual)9.66x

Quick Ratio (Quarterly)13.98x

3-Month Avg Trading Volume0.10M

52-Week Price Return-15.40%

EV / Free Cash Flow (Annual)12.00x

P/E Incl Extra (TTM)16.15x

Tangible BV / Share (Quarterly)$0.26

P/S Ratio (Annual)5.53x

Asset Turnover (Annual)0.35x

52-Week High$9.99

Operating Margin (5Y Avg)53.16%

EPS Excl Extra (Annual)$0.51

CapEx CAGR (5Y)-19.60%

Tangible BV CAGR (5Y)-22.79%

26-Week Price Return-9.17%

Quick Ratio (Annual)9.25x

13-Week Price Return18.70%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)14.64x

Enterprise Value$350.51M

Revenue / Share Growth (5Y)23.50%

Asset Turnover (TTM)0.36x

Book Value / Share Growth (5Y)26.92%

Inventory Turnover (Annual)0.46x

Pretax Margin (Annual)54.26%

Cash / Share (Annual)$3.20

3-Month Return Std Dev33.66%

Gross Margin (5Y Avg)95.03%

EBITDA CAGR (5Y)28.51%

EBITDA Interim CAGR (5Y)13.15%

ROE (Last FY)15.02%

Net Interest Coverage (Annual)14.08x

EPS Basic Excl Extra (Annual)$0.51

P/FCF (TTM)13.11x

Receivables Turnover (TTM)5.86x

EV / Free Cash Flow (TTM)12.22x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$0.46

Receivables Turnover (Annual)3.54x

ROI (TTM)13.26%

Dividend Growth Rate (5Y)14.96%

P/S Ratio (TTM)5.46x

Pretax Margin (5Y Avg)53.57%

Revenue / Share (Annual)$1.35

Tangible BV / Share (Annual)$0.26

Forward P/E13.22x

Free OCF CAGR (5Y)25.13%

Price vs S&P 500 (52W)-33.71%

P/E Ratio (TTM)16.15x

EPS Growth TTM (YoY)-16.30%

Year-to-Date Return-14.93%

5-Day Price Return1.92%

EPS Normalized (Annual)$0.51

ROA (5Y Avg)16.36%

Net Profit Margin (Annual)38.07%

Month-to-Date Return17.00%

Cash Flow / Share (TTM)$0.43

EBITD / Share (Annual)$0.67

EPS Growth (3Y)21.21%

Operating Margin (Annual)48.13%

LT Debt / Equity (Annual)0.42x

P/CF (TTM)12.98x

ROI (5Y Avg)18.43%

P/E Excl Extra (TTM)16.15x

LT Debt / Equity (Quarterly)0.42x

EPS Basic Excl Extra (TTM)$0.46

P/TBV (Quarterly)5.03x

Payout Ratio (Annual)6.92%

P/B Ratio (Annual)2.16x

Dividend / Share (TTM)$0.04

Inventory Turnover (TTM)0.59x

Pretax Margin (TTM)45.90%

Book Value / Share (Annual)$3.44

Price vs S&P 500 (13W)15.91%

Net Margin Growth (5Y)-3.47%

Dividend Yield (TTM)0.48%

Beta0.31x

P/FCF (Annual)12.88x

Revenue / Share (TTM)$1.36

ROE (TTM)13.29%

52-Week Low$5.98

vGradeC

gGradeC

mGradeC

vgmGradeC

CUVL Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.27

Industry Peers(1)

Symbol	Value Score	Growth Score	Momentum Score	Price
CUVLClinuvel Pharmaceuticals Limited American Depositary Shares	C	C	C	$7.60
CRESWCresud S.A.C.I.F. y A. Warrant	—	—	D	$0.00

About Clinuvel Pharmaceuticals Limited American Depositary Shares

Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.